NCT05833815View on ClinicalTrials.gov

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Gallbladder Cancer
Interventions
DRUG

Everolimus 10 mg

Oral Everolimus 10 mg daily in addition to standard of care i.e. GemOx or CapOx

DRUG

Standard of care

GemOx or CapOx

Trial Locations (1)

221010

RECRUITING

Banaras Hindu University, Varanasi

All Listed Sponsors
lead

Banaras Hindu University

OTHER